首页> 外文期刊>Urology >Prognostic Value of Neutrophil-to-lymphocyte Ratio and Establishment of Novel Preoperative Risk Stratification Model in Bladder Cancer Patients Treated With Radical Cystectomy
【24h】

Prognostic Value of Neutrophil-to-lymphocyte Ratio and Establishment of Novel Preoperative Risk Stratification Model in Bladder Cancer Patients Treated With Radical Cystectomy

机译:中性粒细胞与淋巴细胞比率的预后价值以及新型膀胱癌根治性膀胱切除术患者术前风险分层模型的建立

获取原文
获取原文并翻译 | 示例
       

摘要

Preoperative prognostic factors in bladder cancer patients have not been fully established. This study was undertaken to investigate preoperative prognostic factors, including neutrophil-to-lymphocyte ratio (NLR), and to develop a novel prognostic factors-based risk stratification model for disease-specific survival (DSS) in bladder cancer patients treated with radical cystectomy (RC).We performed a retrospective analysis of 189 consecutive bladder cancer patients treated with RC at our institution. Prognostic value of the preoperative clinical and laboratory parameters were evaluated by univariate and multivariate Cox proportional hazard model analyses, and patients were stratified according to relative risks (RRs) for DSS.One-, 3-, and 5-year DSS rates were 86.8%, 70.8%, and 61.7%, respectively. In univariate analysis, tumor size, clinical T stage, hydronephrosis, concomitance of carcinoma in situ, and some laboratory findings (hemoglobin [Hb] level, platelet count, C-reactive protein, neutrophil count, lymphocyte count, and NLR) were significantly associated with poor prognosis. In multivariate analysis, tumor size, hydronephrosis, Hb level, and NLR were independent factors for predicting poor prognosis. Patients were stratified into 3 risk groups: low (RR = 1.000-3.717), intermediate (RR = 4.149-9.315), and high (RR = 10.397-38.646). The differences among the groups were significant.NLR was an independent prognostic factor, as were tumor size, hydronephrosis, and Hb levels, and the combination of these factors can stratify DSS risks in bladder cancer patients treated with RC. This information may be useful for identifying patients who might be candidates for clinical trials of multimodal treatment strategies, including innovative neoadju-vant treatments.
机译:膀胱癌患者的术前预后因素尚未完全确立。这项研究旨在调查术前预后因素,包括嗜中性白细胞与淋巴细胞之比(NLR),并开发基于新颖预后因素的膀胱癌根治性膀胱切除术患者疾病特异性生存(DSS)风险分层模型。 RC)。我们对我们机构中189例接受RC治疗的连续性膀胱癌患者进行了回顾性分析。通过单因素和多因素Cox比例风险模型分析评估术前临床和实验室参数的预后价值,并根据DSS的相对风险(RR)对患者进行分层。一年,三年和5年DSS发生率为86.8%。 ,70.8%和61.7%。在单变量分析中,肿瘤大小,临床T分期,肾积水,原位癌的合并症和一些实验室检查结果(血红蛋白[Hb]水平,血小板计数,C反应蛋白,中性粒细胞计数,淋巴细胞计数和NLR)显着相关预后不良。在多变量分析中,肿瘤大小,肾积水,血红蛋白水平和NLR是预测不良预后的独立因素。将患者分为3个风险组:低(RR = 1.000-3.717),中度(RR = 4.149-9.315)和高(RR = 10.397-38.646)。各组之间的差异非常显着。NLR是独立的预后因素,肿瘤大小,肾积水和Hb水平也是独立的预后因素,这些因素的组合可以对RC治疗的膀胱癌患者进行DSS风险分层。该信息对于识别可能成为多模式治疗策略(包括创新性新辅助治疗)临床试验候选者的患者可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号